1. Home
  2. MTR vs CHRO Comparison

MTR vs CHRO Comparison

Compare MTR & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTR
  • CHRO
  • Stock Information
  • Founded
  • MTR 1979
  • CHRO 2002
  • Country
  • MTR United States
  • CHRO United States
  • Employees
  • MTR N/A
  • CHRO N/A
  • Industry
  • MTR Oil & Gas Production
  • CHRO
  • Sector
  • MTR Energy
  • CHRO
  • Exchange
  • MTR Nasdaq
  • CHRO Nasdaq
  • Market Cap
  • MTR 11.7M
  • CHRO 10.7M
  • IPO Year
  • MTR N/A
  • CHRO 2024
  • Fundamental
  • Price
  • MTR $6.26
  • CHRO $1.66
  • Analyst Decision
  • MTR
  • CHRO Strong Buy
  • Analyst Count
  • MTR 0
  • CHRO 1
  • Target Price
  • MTR N/A
  • CHRO N/A
  • AVG Volume (30 Days)
  • MTR 3.8K
  • CHRO 28.9K
  • Earning Date
  • MTR 01-01-0001
  • CHRO 03-18-2025
  • Dividend Yield
  • MTR 2.86%
  • CHRO N/A
  • EPS Growth
  • MTR N/A
  • CHRO N/A
  • EPS
  • MTR 0.35
  • CHRO N/A
  • Revenue
  • MTR $966,169.00
  • CHRO N/A
  • Revenue This Year
  • MTR N/A
  • CHRO N/A
  • Revenue Next Year
  • MTR N/A
  • CHRO N/A
  • P/E Ratio
  • MTR $18.31
  • CHRO N/A
  • Revenue Growth
  • MTR N/A
  • CHRO N/A
  • 52 Week Low
  • MTR $5.60
  • CHRO $0.45
  • 52 Week High
  • MTR $11.99
  • CHRO $3.80
  • Technical
  • Relative Strength Index (RSI)
  • MTR 51.57
  • CHRO 46.75
  • Support Level
  • MTR $6.18
  • CHRO $1.59
  • Resistance Level
  • MTR $6.54
  • CHRO $2.36
  • Average True Range (ATR)
  • MTR 0.08
  • CHRO 0.25
  • MACD
  • MTR 0.03
  • CHRO -0.03
  • Stochastic Oscillator
  • MTR 61.11
  • CHRO 21.05

About MTR Mesa Royalty Trust

Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.

About CHRO Chromocell Therapeutics Corporation

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Share on Social Networks: